Education
About Us
Working with TipRanks
Follow Us
Can-Fite BioPharma (CANF)
:CANF
Total Valuation
Can-Fite BioPharma has a market cap or net worth of $24.49M. The enterprise value is $5.58M.
Market Cap$24.49M
Enterprise Value$5.58M
Share Statistics
Can-Fite BioPharma has 26,184,248 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,184,248
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Can-Fite BioPharma’s return on equity (ROE) is -1.45 and return on invested capital (ROIC) is -113.33%.
Return on Equity (ROE)-1.45
Return on Assets (ROA)-0.86
Return on Invested Capital (ROIC)-113.33%
Return on Capital Employed (ROCE)-1.15
Revenue Per Employee134.80K
Profits Per Employee-1.58M
Employee Count5
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Can-Fite BioPharma is ―. Can-Fite BioPharma’s PEG ratio is 0.04.
PE Ratio―
PS Ratio17.54
PB Ratio2.18
Price to Fair Value2.18
Price to FCF-1.55
Price to Operating Cash Flow-1.26
PEG Ratio0.04
Income Statement
In the last 12 months, Can-Fite BioPharma had revenue of 674.00K and earned -7.88M in profits. Earnings per share was -1.08.
Revenue674.00K
Gross Profit674.00K
Operating Income-8.13M
Pretax Income-7.88M
Net Income-7.88M
EBITDA-8.12M
Earnings Per Share (EPS)-1.08
Cash Flow
In the last 12 months, operating cash flow was -8.35M and capital expenditures -2.00K, giving a free cash flow of -8.36M billion.
Operating Cash Flow-8.35M
Free Cash Flow-8.36M
Free Cash Flow per Share-0.32
Dividends & Yields
Can-Fite BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.16
52-Week Price Change-82.88%
50-Day Moving Average0.39
200-Day Moving Average0.85
Relative Strength Index (RSI)31.80
Average Volume (3m)258.05K
Important Dates
Can-Fite BioPharma upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 21, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Can-Fite BioPharma as a current ratio of 4.38, with Debt / Equity ratio of 2.15%
Current Ratio4.38
Quick Ratio4.38
Debt to Market Cap<0.01
Net Debt to EBITDA0.58
Interest Coverage Ratio-580.71
Taxes
In the past 12 months, Can-Fite BioPharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Can-Fite BioPharma EV to EBITDA ratio is -0.87, with an EV/FCF ratio of -0.93.
EV to Sales10.54
EV to EBITDA-0.87
EV to Free Cash Flow-0.93
EV to Operating Cash Flow-0.93
Balance Sheet
Can-Fite BioPharma has $6.46M in cash and marketable securities with $90.00K in debt, giving a net cash position of $6.37M billion.
Cash & Marketable Securities$6.46M
Total Debt$90.00K
Net Cash$6.37M
Net Cash Per Share$0.24
Tangible Book Value Per Share$0.75
Margins
Gross margin is 100.00%, with operating margin of -1206.23%, and net profit margin of -1169.14%.
Gross Margin100.00%
Operating Margin-1206.23%
Pretax Margin-1169.14%
Net Profit Margin-1169.14%
EBITDA Margin-1205.19%
EBIT Margin-1206.23%
Analyst Forecast
The average price target for Can-Fite BioPharma is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.50
Price Target Upside900.00% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―